Introduction
Focal cortical dysplasia (FCD) type II is a frequent cause of drugresistant focal epilepsy [1] . It belongs to the group of malformations of cortical development, characterized pathologically by the presence of dysmorphic neurons in type IIa lesions and additionally by balloon cells in type IIb [2] [3] [4] . The identification of FCD by MR imaging allows patients with pharmaco-resistant epilepsy to undergo resective surgery, which yields rates of seizure-freedom of 70-80% [5] [6] [7] . However, MRI characteristics of FCD are variable and the detection of such a lesion remains challenging [7] [8] [9] [10] . Moving to higher MR field strengths and with the help of computer-aided detection systems such as morphometric MRI analysis [7, 11] , the identification of very small and sometimes questionable malformations of cortical development becomes feasible.
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have shown alterations of relative N-acetyl-aspartate (NAA) to choline (Cho) and total creatine (Cr) ratios [12] [13] [14] [15] [16] [17] . These valuable studies, however, comprise very small and heterogeneous populations and lack histological confirmation of FCD in most cases [12] [13] [14] [15] [16] [17] [18] [19] . The identification of a potential epileptogenic lesion in MRI is crucial for patients with pharmaco-resistant epilepsy, as it considerably improves the chances of postsurgical seizure-freedom. In people without apparent MRI lesions, in turn, the identification of a pathology in brain biopsy predicts a better seizure outcome after surgery [6] . Before performing invasive presurgical diagnostics in suspected lesions or ''MRI-negative'' cases, an additional noninvasive test is desirable to sustain the suspicion of FCD II. The aim of the present study was to characterize the metabolic composition of MR-tomographically typical and partly also neuropathologically confirmed FCDs using high-field clinical 1 H MRS.
Methods

Clinical data
We performed single-volume 1 H MRS in 13 patients with pharmaco-resistant epilepsy due to FCD as assessed by brain MRI. All patients were in-patients of the Department of Epileptology at the University of Bonn suffering from medically refractory epilepsy who were evaluated for epilepsy surgery. The study protocol was approved by the ethics committee of the University hospital and patients or their caregivers gave written informed consent. All studies were performed at an inter-ictal state, which was determined by clinical observation, or in cases of auras, by selfreports. Patients were receiving their standard regimen of antiepileptic drugs.
To date, in seven patients surgery was performed. In three cases FCD IIa and in four patients FCD IIb according to Palmini and Lü ders [2] was confirmed histologically. In one of the remaining patients, FCD was located in the Broca area according to intralesionally implanted electrodes, so that surgery was not possible, and five patients have declined surgery to date.
Clinical features such as the age at onset of seizures, the seizure frequency, the neuropathological diagnosis and the clinical outcome were assessed (see Table 1 ).
MRI
All thirteen patients were examined at a 3 T clinical MR scanner prior to 1 H MRS. Routine epilepsy MRI was performed in all patients [20] . The localisations of the spectroscopic target volumes were planned in high resolution T1-weighted, T2-weighted and in FLAIR images. Conventional visual analysis of the structural MRI was done by two neuroradiologists in consensus. A FCD II was diagnosed if the following criteria were fulfilled: (1) blurring of grey and white matter junction; (2) focal thickening of the cortex; (3) increased signal on FLAIR/T2 in the subcortical white matter; (4) extension of cortical tissue with increased signal from the surface to the ventricle (transmantle dysplasia) or funnel-shaped extension of subcortical high signal to the ventricle (bottom-of-sulcus dysplasia) [21] . The size of the FCD was classified according to the following scheme: Small: 1 sulcus or 1 gyrus AE adjacent sulci, including bottom-of-sulcus dysplasia, crown-of-gyrus dysplasia and crown-of-gyrus & bottom-of-sulcus dysplasia; Medium: 2 adjacent gyri; Large: !3 adjacent gyri.
The details on MRI analysis can be found in Table 1 .
1 H MRS
Proton MRS was performed at a clinical 3 T system in all cases (Achieva TX or Ingenia TX, Philips Healthcare, Best, the Netherlands) using a SENSE receive-only 8-channel head coil (twelve patients) or a transmit/receive head coil (one patient).
In each investigation, proton spectra were acquired in two volumes of interest (VOI). The first VOI was placed in the FCD including the dysplastic cortex and the adjacent hyperintense area in the subcortical white matter (Fig. 1 ). With exception of patient 4, who had a very large lesion of the left frontal lobe (Fig. 2) , the spectroscopic volumes fully encompassed the FCDs. The mean target volume size was 6.3 ml (range 4-12 ml). The volume was planned as small as possible in order to exclude the adjacent normal brain tissue from the FCD target volume. As a control volume, an identically sized VOI was positioned in a mirror region of normal appearing brain tissue in the contralateral hemisphere.
The MRS protocol included acquisition of water-suppressed proton spectra with PRESS volume selection [22] , TR/TE 2000/140 and 30 ms, and 128 signal averages. The TE of 140 ms was chosen for in-phase detection of the Ch 3 -doublet of lactate, and signal loss caused by its anomalous J-coupling [23] was compensated by increasing the refocusing pulse bandwidth. Absolute quantification of metabolite concentrations was provided by non-water suppressed spectra with TR/TE 3500/ 80 ms using the brain water signal as an internal reference. Metabolite concentrations were corrected for partial volume effects by bi-exponential fitting of the T2-values and the relative fractions of brain tissue water and CSF to an additional set of 7 unsuppressed spectra with TR/TE 1-7 6000/35-800 ms. The whole set of water-suppressed and unsuppressed spectra took about 15 min for each hemisphere. For reason of time, no spectra at TE 30 ms could be acquired for patients 3 and 7 so that for these patients, we did not measure Ins values.
Relative and absolute concentrations of N-acetyl-aspartate (NAA), total creatine (Cr), choline containing compounds (Cho), myo-inositol (Ins), glutamine (Gln), glutamate/glutamine/GABA (Glx), and lactate were determined after time-domain fitting of the acquired MR spectra using the AMARES algorithm of the MRUI software package [24, 25] . Lower part of the figure: The MR spectra in the lesion (target volume, left side) show an increase in Cho (arrow pointing upwards) and a decrease in NAA (arrow pointing downwards) in comparison to the control region (right side).
Statistical analysis
Group analysis was performed using the Wilcoxon signed-rank test for matched pairs and Spearman-Rho. P < 0.05 was considered statistically significant. Taking into account the regional differences of metabolite signals, only intra-individual statistical comparisons of the absolute metabolite concentrations and the metabolite ratios (metabolite signal with respect to that of Cr) were calculated (Table 2) . Absolute metabolite concentrations and metabolite ratios were correlated with clinical data and imaging data: seizure frequency per day, duration of epilepsy, postoperative outcome and size of the lesion. Statistical analysis was performed using SPSS software package Version 21 (IBM, Armonk, NY).
Results
1 H MRS
Matched pair-analysis of metabolite ratios showed a mean relative increase in Cho/Cr of 26% (p = 0.012) and a reduction in NAA/Cr of 21% (p = 0.001) in FCD lesion as compared to those acquired from the control voxel in the contralateral hemisphere. Absolute quantification of metabolites revealed that these differences were caused by a significant increase in Cho of 32% (p = 0.015) and a significant decrease in NAA concentration of 13% (p = 0.008) in the lesions. No significant differences were detected for Ins/Cr, Gln/Cr and Glx/Cr metabolite ratios.
Although mean values of Cr and Ins concentration were higher in the FCD lesions by about 5% and 36%, respectively, matched-pair analysis showed no significant differences of these metabolite concentrations between FCD lesions and control regions (p = 0.110 and p = 0.051), as differences were small for Cr and individual findings were variable for Ins (see Table 2 and Fig. 3 for details). Lactate was detected in FCD spectra of two patients (patients 3 and 7).
Compared to the unaffected contralateral side, there was a significant positive correlation between the Cr concentration in the FCD lesion, and the frequency of seizures per day (Spearman-Rho r = 0.898; p = 0.002), while no significant correlation was found between lesional concentrations of NAA, Cho, and Ins and the seizure frequency. Fig. 3 . Scatterplot displays the relative differences of the metabolite ratios between the lesion and the normal appearing contralateral hemisphere (zero line) for each of the 13 subjects. There was a decrease in relative NAA/Cr (upside down triangle) in all patients and a significant increase in Cho/Cr in 10/13 FCDs (triangle). Individual findings for Ins/Cr (rhombus) were ambiguous. No Ins measurements could be acquired for patients 3 and 7 for reason of time. Other clinical and imaging features such as the duration of epilepsy, the post-operative seizure outcome and the size of the lesion did not show any significant association with metabolic results.
Discussion
Using 3 T
1 H MR spectroscopy, we found a significant increase in Cho and a reduction of NAA in patients with focal epilepsy due to FCDs II. Our results are in line with previous reports on small groups of FCD-patients investigated at 1.5 T [12, 14, 17, 18 ] and 3 T [16] , and with a study at an experimental high field 4.1 T MR scanner [13] . Most of these studies described heterogeneous populations including patients with malformations of cortical development or low-grade brain tumours [19, 26] with a few FCD cases included [12] [13] [14] [15] 17, 18, 27] . While in the literature, most authors report on a predominant NAA reduction [15] [16] [17] [18] 26] , our study is in accordance with Lundbom [12] where Cho was most significantly elevated. However, Cho increase and NAA decrease in the FCDs appeared to be less pronounced than in low-grade brain tumours [19, 26] . Metabolic disturbances in cortical dysplasia are mainly explained by disorganization of tissue architecture with areas of immature and even undifferentiated cells [13, 28] . FCD spectra with low concentrations of NAA combined with elevated Cho and Ins resemble normal brain spectra of young children [29] . In contrast to that, in polymicrogyria the NAA/Cr ratio is reported to be normal, which is explained by the fact that in polymicrogyria the injury is postmigrational and the neurons are mature [18] . Another explanation for the observed metabolic abnormalities with decreased NAA and increased Cho is neuronal cell loss in combination with gliosis as discussed in hippocampal sclerosis [30] [31] [32] . Metabolic abnormalities were also described in the contralateral hippocampus of people with temporal lobe epilepsy due to unilateral hippocampal sclerosis and in people with temporal lobe epilepsy in the absence of apparent MRI lesions, albeit to a lesser extent [33, 34] . Postoperative normalization of metabolites on the non-operated side was observed [28, 33, 34] , which led to the assumption that the reversible NAA reduction in the non-operated side is due to neuronal and glial dysfunction and not to neuronal loss [28] . In our study, we used an intra-individual approach, placing a voxel in the lesion and a control voxel in the normal appearing contralateral side, as substantial regional [35] and age-dependent [36] variations in healthy brain spectra but no significant differences between the two hemispheres [37] are known. Simone et al. [15] also used the normal appearing contralateral side as the control region and additionally compared their results with that of healthy volunteers, while other authors only used healthy volunteer brain metabolism for comparison to an FCD lesion [12, 13, 17, 26] .
In our study the mean absolute concentration of Cr in the FCD lesions did not differ significantly from the concentration measured in the contralateral control voxel (Table 2 ). However, there was a significant positive correlation between the Cr concentration in the lesion and the frequency of seizures per day. In that respect previous studies provided conflicting data. While our results are in line with the work of Kuzniecky and colleagues [13] , other authors [15, 18] did not find any correlation between metabolite concentrations and the frequency of seizures. Creatine is a marker for energy metabolism, and possibly epileptogenic areas may have higher metabolism even at an inter-ictal state. Another potential explanation for an increase of Cr in cerebral lesions could be astrogliosis. Some in vitro studies of cultured neuronal and glial cells [38, 39] suggested that the Cr concentration is higher in astrocytes than in neurons. Elevated Cr in some studies of patients with multiple sclerosis [40] and in patients with temporal lobe epilepsy [31] has therefore been interpreted as an indication of gliosis. In FCDs, gliosis is an additional feature [5] , and balloon cells, hallmark of type IIb FCDs [2] , occasionally are positive for the glial marker GFAP (glial fibrillary acid protein) [2, 5] .
Other clinical or imaging features such as the duration of epilepsy, the post-operative outcome or the size of the lesion did not correlate with metabolic parameters, which is in accordance with the literature [12, 15, 18] .
Based on clinical observation and self-reports, patients were scanned at an inter-ictal state. However, we found lactate in the FCD lesions of two patients. Accumulation of lactate is usually reported in the epileptogenic focus during or shortly after seizures [15] . Lactate signal can increase probably due to either enhanced glycolysis by alkalotic stimulation of phosphofructokinase or reduced lactate clearance in the observed tissue volume [15] . We thus scrutinized the medical histories of the two patients with increased lactate and realized that patient No. 7 had a complexpartial seizure six hours before the MRI, whereas patient No. 3 was seizure-free 36 h prior to the MRI. Thus, in the latter case there was no clinically apparent or self-reported seizure to explain the presence of lactate. As FCDs are intrinsically epilptogenic foci, one might speculate that the presence of lactate could reflect this abnormal activity even in the absence of clinical seizure.
The present study has some limitations: The inter-ictal state was determined, as done in most studies, according to self-reports and clinical observations, and not by continuous video-EEG recordings prior to MRI, giving rise to some uncertainty with respect to the true inter-ictal state. Considering lactate (see above) as a seizure-related marker, this uncertainty might be a problem in one of our patients only. Furthermore, the intra-individual approach and the contamination of the voxel with perilesional normal tissue are possible limitations of our study, as the FCD effects might even be underestimated. Not all patients had histological confirmation of the FCD. Finally, we did not examine patients with lesions other than FCDs. Low grade glioma is a differential diagnosis to FCD in patients with seizures and a focal lesion [19, 26] . Loss of NAA and increase in Cho are shared features. However, in gliomas, increase in Cho is accompanied by a distinct reduction of NAA [19, 26] , while the NAA decrease in FCD was comparatively less pronounced. Inflammatory changes like in multiple sclerosis show a comparable metabolite pattern with mild decrease of NAA and increase in Cho [41] , but usually this is not a differential diagnosis on conventional MR imaging.
Conclusion
Our results suggest that the spectroscopic detection of metabolic changes typically linked to FCD may help to differentiate FCD-suspicious lesions from normal brain tissue with a higher degree of certainty. The clinical value of this novel approach, however, has to be tested in further studies investigating more subtle lesions (i.e. without transmantle sign) with subsequent histopathological confirmation after resective epilepsy surgery.
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